Health Affairs, 23, no. 3 (2004): 269-276 doi: 10.1377/hlthaff.23.3.269 © 2004 by Project HOPE	New Online   How Would Obama, McCain Cover The Uninsured?   Debating Cost Of Uninsured   Try Medicare-For-All   HA Blog Top 10

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Morgan, S. Articles by Mintzes, B. Search for Related Content PubMed PubMed Citation Articles by Morgan, S. Articles by Mintzes, B. Related Collections Access To Care Business Of Health Health Reform International Issues Pharmaceuticals Health Spending

UpDate

INTERNATIONAL REPORT

Outcomes-Based Drug Coverage in British Columbia

For the past decade the provincial drug plan in British Columbia has based the allocation of public subsidy on scientific standards of evidence. Coverage policies under B.C. PharmaCare are marked by the restriction of public subsidy until manufacturers provide valid evidence of a comparative health outcome advantage versus therapeutic alternatives. Implementing and maintaining such outcomes-based coverage policies has required a system of evidentiary review and support. Since 1994 the Therapeutics Initiative at the University of British Columbia has provided provincial decisionmakers with such support. We describe lessons from the B.C. experience for jurisdictions interested in basing coverage on evidence of proven comparative advantage for patients’ health.

                      What's this?

This article has been cited by other articles:

				B. Mintzes Direct to consumer advertising of prescription drugs BMJ, September 2, 2008; 337(sep02_1): a985 - a985. [Full Text]

				C. A. Jackevicius, J. V. Tu, J. S. Ross, D. T. Ko, and H. M. Krumholz Use of Ezetimibe in the United States and Canada N. Engl. J. Med., April 24, 2008; 358(17): 1819 - 1828. [Abstract] [Full Text] [PDF]

				J. M. Paterson, A. Laupacis, K. Bassett, G. M. Anderson, and for the BC-Ontario Pharmacosurveillance for Decisi Using Pharmacoepidemiology To Inform Drug Coverage Policy: Initial Lessons From A Two-Province Collaborative Health Aff., September 1, 2006; 25(5): 1436 - 1443. [Abstract] [Full Text] [PDF]

				J. Hsu, M. Price, J. Huang, R. Brand, V. Fung, R. Hui, B. Fireman, J. P. Newhouse, and J. V. Selby Unintended consequences of caps on medicare drug benefits. N. Engl. J. Med., June 1, 2006; 354(22): 2349 - 2359. [Abstract] [Full Text] [PDF]

				S. G. Morgan, M. McMahon, C. Mitton, E. Roughead, R. Kirk, P. Kanavos, and D. Menon Centralized drug review processes in australia, Canada, new zealand, and the United kingdom. Health Aff., March 1, 2006; 25(2): 337 - 347. [Abstract] [Full Text] [PDF]